Asio Capital LLC Decreases Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Asio Capital LLC decreased its position in HCA Healthcare, Inc. (NYSE:HCA) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 16,983 shares of the company’s stock after selling 378 shares during the period. HCA Healthcare comprises approximately 1.0% of Asio Capital LLC’s portfolio, making the stock its 28th biggest holding. Asio Capital LLC’s holdings in HCA Healthcare were worth $5,097,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. MML Investors Services LLC raised its stake in HCA Healthcare by 31.7% in the 3rd quarter. MML Investors Services LLC now owns 17,816 shares of the company’s stock valued at $7,241,000 after purchasing an additional 4,285 shares during the last quarter. Meritage Group LP purchased a new position in shares of HCA Healthcare during the third quarter valued at approximately $150,548,000. Galvin Gaustad & Stein LLC acquired a new position in HCA Healthcare in the 4th quarter valued at $18,044,000. Alpha DNA Investment Management LLC purchased a new stake in shares of HCA Healthcare in the third quarter valued at $869,000. Finally, NRI Wealth Management LC acquired a new stake in HCA Healthcare in the 4th quarter worth about $2,896,000. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Stock Down 4.0 %

Shares of NYSE:HCA opened at $312.51 on Friday. The firm has a market cap of $79.16 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. HCA Healthcare, Inc. has a 12-month low of $279.93 and a 12-month high of $417.14. The company has a fifty day simple moving average of $313.49 and a 200 day simple moving average of $352.62.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same quarter last year, the firm earned $5.90 earnings per share. On average, equities research analysts anticipate that HCA Healthcare, Inc. will post 21.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. The trade was a 29.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the transaction, the senior vice president now directly owns 52,702 shares in the company, valued at $18,445,700. This represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $392.00 target price on shares of HCA Healthcare in a research report on Tuesday, October 1st. Barclays lowered their price objective on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Raymond James downgraded HCA Healthcare from an “outperform” rating to a “market perform” rating in a research report on Friday, November 22nd. Oppenheimer boosted their target price on HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a report on Monday, October 28th. Finally, Truist Financial decreased their price objective on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, January 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, HCA Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $385.27.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.